If you’re excited about tamiflu and steadily growing stockpiles, consider this:
“To date, most patients with H5N1 have been treated with Tamiflu. Studies of Tamiflu for use in H5N1 influenza have produced varying results. Two studies of patients with H5N1 influenza in 2004 and 2005 revealed no difference in outcome between those who received Tamiflu and those who did not. However, some of the patients received an antiviral only later in the disease, and the studies were not large enough to produce meaningful conclusions. ‘The numbers are so small that it’s hard to know whether Tamiflu is efficacious at mitigating disease, but it’s all we have, so it’s worth trying because it has very limited toxicity’ says Stephanie Black, MD, assistant professor of medicine at Rush University Medical Center in Chicago.” The good thing about Tamiflu is that it doesn’t do any harm, in other words.
“A 2007 study of the effectiveness of Tamiflu in improving the survival rate of ferrets exposed to the H5N1 virus found that giving the drug within 4 hours of exposure (ie, before illness) resulted in 100% survival. When the treatment was delayed 24 hours after exposure, a higher dose was needed to achieve the same result.” 4 hours, 24 hours: this is obviously not a very realistic temporal frame for pandemic times.
The practice of stockpiling Tamiflu makes preparedeness visible, tangible, and countable. “You can count on it,” as an expert phrased it. At the same time, neither the federal nor state governments have been willing to invest in things like ventilators and hospital beds. In this domain a different rationality prevails: The rationality of prioritization.